However, tumor-infiltrating CD8 + T cells remained low for both AMD3100 and P-BS-CM1 → P-CM2, aligning with previous studies showing CXCR4 blockade alone is insufficient to activate anti-tumor immunity12,22. This evidence concerns the gene CXCR4 and neoplasm.